Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
9
×
life sciences
national blog main
national top stories
biotech
clinical trials
new york blog main
new york top stories
san diego blog main
san diego top stories
san francisco blog main
deals
raleigh-durham blog main
raleigh-durham top stories
san francisco top stories
alnylam pharmaceuticals
boulder/denver blog main
boulder/denver top stories
bristol-myers squibb
detroit blog main
detroit top stories
fda
indiana blog main
indiana top stories
intercept pharmaceuticals
national
new york
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
alexion pharmaceuticals
boston
celgene
drugs
hepatitis b
What
disease
9
×
drug
9
×
approved
medicines
fda
liver
new
bio
fatty
gene
help
hepatitis
known
medicine
nash
patients
pharma
pharmaceuticals
race
roundup
stop
treatment
year
acorda
adds
advanced
ago
akcea
alliance
alnylam
alnylam’s
alternative
alzheimer's
amyloidosis
approval
areas
attr
autoimmune
available
bad
Language
unset
Current search:
disease
×
drug
×
" boston top stories "
×
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com
4 years ago
Can Tiny Drug Doses (and One Woman’s Fortune) Fight the Most Vicious Cancer?
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com
5 years ago
Acorda Gets FDA Nod For New Parkinson’s Drug, But Rival Looms
@xconomy.com
5 years ago
Brii Bio’s Alliance with VBI Vaccines Adds Hepatitis B Drug to Pipeline